The iPSC vaccine significantly increased CD8+ cytotoxic T cell frequency in the tumor TDLN and promoted T cell activation and antitumor cytokine production (IFN-γ and IL-2) in T lymphocytes, and increased cancer cell-specific antibodies in B cells. Here, CD8A is linked to neoplasm.